Bioiberica to present four clinical research communications at the annual meeting of the American College of Rheumatology

The 2017 Annual Meeting of the American College of Rheumatology will have an unprecedented educational content, with more than 450 scientific sessions. These sessions include updates on some of the most relevant advances worldwide in research and clinical applications for rheumatologists.

Bioiberica will actively participate in the meeting, presenting four clinical research communications in osteoarthritis:

• Differences in Serum Protein Biomarkers Between Combined Glucosamine and Chondroitin versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients.

• Orosomucoid 2 Serves as a Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride.

• Chondroitin Sulfate/Glucosamine Hydrochloride Induces a Reduction in Adrenergic Serum Markers in Osteoarthritis Patients Similar to that Produced by Celecoxib.

• Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI.

All these studies will be presented in separate sessions that will take place on November 6, the day dedicated to education in osteoarthritis.

These studies are being carried out thanks to the collaboration between Bioiberica and various universities and research centers which are developing the most advanced clinical essays in osteoarthritis biomarkers. Their findings will allow us to determine the best treatments for osteoarthritis patients. As Dr Marta Herrero, head of clinical development at Bioiberica’s Human Health Division, commented, these studies represent “a clear example of Bioiberica’s commitment to clinical research in osteoarthritis”.

Bioiberica is a company with more than 40 years of experience under their belt in the identification and production of biomolecules for the pharmaceutical industry. It is the only international firm that has developed three chondroprotective molecules: glucosamine, hyaluronic acid, and chondroitin sulfate, of which it is the leading producer worldwide.

Reference list:

• Differences in Serum Protein Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients. Sandi L. Navarro, Marta Herrero, Helena Martinez, Jon Ladd, Yuzheng Zhang, Edward Lo, David Shelley, Timothy W. Randolph, Yvonne Schwarz, Johanna W. Lampe, Paul D. Lampe

• Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride. Calamia, M. Camacho, I. Rego-Pérez, L. González, P. Fernández-Puente, F. Picchi, M. Herrero, H. Martínez, C. Ruiz-Romero, F. J. Blanco  

• Chondroitin sulfate/Glucosamine hydrochloride induce a reduction in adrenergic serum markers in osteoarthritis patients similar to that produced by Celecoxib. Pedro Zapater, Marta Herrero, Helena Martínez, Rubén Francés, Josep Vergés, Jose F Horga

• Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study. Johanne Martel-Pelletier, Jean-Pierre Raynaul¹, François Mineau, François Abram, Patrice Paiement, Philippe Delorme and Jean-Pierre Pelletier